Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS sets deadline for applications
2005-11-14

The University of the Free State (UFS) calls on all prospective students wishing to study at the UFS in 2006 to submit their applications for admission by no later than 30 November 2005.

“This applies to first-time entering first-year students, senior students who have interrupted their studies for at least one year and undergraduate students from other educational institutions,” said Mr Vernon Collett, Registrar:  Academic Student Services at the UFS.

According to Mr Collett students whose applications for admission are received after 30 November 2005 and until 25 January 2006 will be accepted subject to the availability of place on the programme they applied for. 

“After 30 November 2005 academic advice within a one-stop service may not be available to students and no conditional exemptions will be considered.  No transfer students from other tertiary institutions will also be accepted after 30 November 2005,” said Mr Collett.

Prospective students who want to apply must pay a non-refundable fee of R110 into a designated account, which will be provided when the application form is sent to them.  The signed application form must be accompanied by a certified copy of the prospective student’s identity document or passport and a proof of payment of the application fee.  The application form of a minor must be signed by his/her parent or guardian and the field of study should be clearly indicated.

“A total of 25 251 students are registered at the UFS Main Campus this year.  We expect a considerable number of applications and foresee that our numbers for next year will be similar to what it is now,” said Mr Collett.

First-time entering first-year students on the Main Campus will be welcomed by the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie, on 14 January 2006 at 11:00 in the Callie Human Centre.

The registration of first-time entering first-year students will commence on 17 January 2006 and that of senior students on 23 January 2006 at the Callie Human Centre according to a programme.  Students who applied for admission after 30 November 2005 can register from 2 February 2006.  Lectures will commence on 6 February 2006 and the registration process will end on 11 February 2006.

Prospective students who want to apply for admission or who have any enquiries can call (051) 401-3000 or visit the UFS web site at www.uovs.ac.za.

Media release
Issued by: Lacea Loader
Media Representative
Tel:   (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
14 November 2005

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept